CD44 and gastric cancer: In the subgroup of nodal-positive GC, median RFS was 20.4 months (10–31 months) in patients with moderate CD44 expression and 6.0 months (0–12 months) in patients with high CD44 expression compared to 22.1 months (15–29 months) in patients with CD44 negative GC; median DSS was 25.6 months (13–38 months) in patients with moderate CD44 expression and 7.0 months (0–15 months) in patients with high CD44 expression compared to 41.4 months (28–55 months) in patients with CD44 negative GC.